Thrombotic thrombocytopenic purpura after stenting and ticlopidine

Lancet

Volumn 352, Issue 9133, 1998, Pages 1036-1037

  Bennett, Charles L ^a   Kiss, Joseph E ^b   Weinberg, Peter D ^b   Pinevich, A J ^b   Green, David ^b   Kwaan, Hau C ^b   Feldman, Marc D ^b  

^a NW Univ Feinberg School of Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; TICLOPIDINE;

ARTICLE; CLINICAL ARTICLE; HEART CATHETERIZATION; HEART DISEASE; HEMOLYTIC ANEMIA; HUMAN; KIDNEY DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; STENT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0032569461     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)60079-7     Document Type: Article

References (5)

1. 1 Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998; 128: 541-44.
2. 2 Bennett CL, Green D, Kwaan H, Weinberg PD, Feldman MD. Ticlopidine associated thrombotic thrombocytopenic purpura following cardiac stent placement. N Engl J Med (in press).
3. 3 Ticlid® (ticlopidine HCl) tablets complete product information, June, 1998. Nutley, NJ: Roche Laboratories Inc, 1998.
4. 4 Moore TJ, Psaty BM, Furberg CD. Time to act on drug safety. JAMA 1998; 279: 1571-73.
5. 5 Berger PB, Grill OE, Melby SJ, Bell MR, Holmes Jr DR. Can ticlopidine be safely discontinued two weeks after coronary stent placement? Proc Am Coll Cardiol 1998; 31: 1190-204.